Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Easywell Biomedicals's Enterprise Value is NT$4,238.0 Mil.
Easywell Biomedicals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$109.4 Mil. Therefore, Easywell Biomedicals's EV-to-FCF for today is 38.75.
The historical rank and industry rank for Easywell Biomedicals's EV-to-FCF or its related term are showing as below:
ROCO:1799'
s EV-to-FCF Range Over the Past 10 Years
Min: -274.09 Med: -13.75 Max: 515.27
Current: 38.01
During the past 13 years, the highest EV-to-FCF of Easywell Biomedicals was 515.27. The lowest was -274.09. And the median was -13.75.
ROCO:1799's EV-to-FCF is ranked worse than 68.09% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.815
vs ROCO:1799: 38.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Easywell Biomedicals's PE Ratio (TTM) for today is calculated as:
Easywell Biomedicals's share price for today is NT$32.25.
Easywell Biomedicals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Easywell Biomedicals EV-to-FCF Related Terms
Easywell Biomedicals EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Easywell Biomedicals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easywell Biomedicals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Easywell Biomedicals's EV-to-FCF falls into.
Easywell Biomedicals's current Enterprise Value is NT$4,238.0 Mil.
Easywell Biomedicals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$109.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Easywell Biomedicals (ROCO:1799) has a EV-to-FCF of 38.75 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Easywell Biomedicals and its competitors. According to the industry distribution chart, Easywell Biomedicals ranks #384 out of 564 companies in the Drug Manufacturers industry, placing it in the top 68.1%.
Is Easywell Biomedicals' EV-to-FCF too high?
Easywell Biomedicals' current EV-to-FCF is 38.75. The Drug Manufacturers industry median EV-to-FCF is 20.82. Easywell Biomedicals' value of 38.75 is 86.2% above this industry median. Based on the distribution chart, Easywell Biomedicals ranks #384 out of 564 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Easywell Biomedicals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Easywell Biomedicals ranks #384 out of 564 companies for EV-to-FCF. This places Easywell Biomedicals in the lower half of its industry. The industry median EV-to-FCF is 20.82. Easywell Biomedicals' value of 38.75 is 86.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.82, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Easywell Biomedicals's current EV-to-FCF of 38.75 is 86.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Easywell Biomedicals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Easywell Biomedicals's current EV-to-FCF is 38.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.37, compared to a current price of NT$32.25 — trading 57.2% below its estimated fair value. The current EV-to-FCF is 38.75 and 86.2% above the Drug Manufacturers industry median of 20.82. Easywell Biomedicals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current EV-to-FCF is 38.75 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?
Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued.
The current stock price of NT$32.25 is trading 57.2% below its estimated GF Value™ of NT$75.37.
GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.
Key valuation signals for ROCO:1799:
EV-to-FCF: 38.75
GF Value™: NT$75.37 vs. price of NT$32.25 (57.2% below fair value)
Industry Position: 86.2% above the Drug Manufacturers median (#384 of 564)
No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score
Get the complete analysis for ROCO:1799
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1799 has been successfully added to your 
